The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma (NEO-GLITIPNI).
 
Iris Dirven
Travel, Accommodations, Expenses - AstraZeneca; Merck Serono; Pierre Fabre
 
Louise Lescrauwaet
Travel, Accommodations, Expenses - SERVIER
 
Cleo Bertels
No Relationships to Disclose
 
Latoya Stevens
No Relationships to Disclose
 
Xenia Geeraerts
No Relationships to Disclose
 
Freya Vaeyens
No Relationships to Disclose
 
Anne-Marie Vanbinst
No Relationships to Disclose
 
Hendrik Everaert
No Relationships to Disclose
 
Stefanie Brock
No Relationships to Disclose
 
Sandra Tuyaerts
No Relationships to Disclose
 
Mark Kockx
Leadership - CellCarta
Stock and Other Ownership Interests - CellCarta
 
Johnny Duerinck
No Relationships to Disclose
 
Bart Neyns
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre